No Cover Image

Journal article 319 views 50 downloads

Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice

Marc Evans, Angharad R. Morgan, Steve Bain Orcid Logo, Sarah Davies, Debbie Hicks, Pam Brown, Zaheer Yousef, Umesh Dashora, Adie Viljoen, Hannah Beba, W. David Strain

Diabetes Therapy, Volume: 13, Issue: 2, Pages: 225 - 240

Swansea University Author: Steve Bain Orcid Logo

  • 59059.pdf

    PDF | Version of Record

    ©The Author(s) 2022. This article is licensed under a Creative Commons Attribution NonCommercial 4.0 International License

    Download (763.8KB)

Check full text

DOI (Published version): 10.1007/s13300-021-01201-z

Abstract

While glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, are among the most effective drugs for treating people with type 2 diabetes (T2D), they are clinically under-utilised. Until recently, the only route for semaglutide administration was via subcutaneous injection. Howev...

Full description

Published in: Diabetes Therapy
ISSN: 1869-6953 1869-6961
Published: Springer Science and Business Media LLC 2022
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa59059
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2022-01-04T12:37:57Z
last_indexed 2022-03-15T04:27:23Z
id cronfa59059
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-03-14T13:17:06.2808758</datestamp><bib-version>v2</bib-version><id>59059</id><entry>2022-01-04</entry><title>Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-01-04</date><deptcode>BMS</deptcode><abstract>While glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, are among the most effective drugs for treating people with type 2 diabetes (T2D), they are clinically under-utilised. Until recently, the only route for semaglutide administration was via subcutaneous injection. However, an oral formulation of semaglutide was recently licensed, with the potential to address therapy inertia and increase patient adherence to treatment, which is essential in controlling blood glucose and reducing complications. The availability of oral semaglutide provides a new option for both clinicians and patients who are reluctant to use an injectable agent. This has been of particular importance in addressing the challenge of virtual diabetes care during the COVID-19 pandemic, circumventing the logistical problems that are often associated with subcutaneous medication administration. However, there remains limited awareness of the clinical and economic value of oral semaglutide in routine clinical practice. In this article, we present our consensus opinion on the role of oral semaglutide in routine clinical practice and discuss its value in reducing the burden of delivering diabetes care in the post-COVID-19 pandemic period of chronic disease management.</abstract><type>Journal Article</type><journal>Diabetes Therapy</journal><volume>13</volume><journalNumber>2</journalNumber><paginationStart>225</paginationStart><paginationEnd>240</paginationEnd><publisher>Springer Science and Business Media LLC</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1869-6953</issnPrint><issnElectronic>1869-6961</issnElectronic><keywords>Glucagon-like peptide-1 receptor agonists; Oral semaglutide; Type 2 diabetes</keywords><publishedDay>1</publishedDay><publishedMonth>2</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-02-01</publishedDate><doi>10.1007/s13300-021-01201-z</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2022-03-14T13:17:06.2808758</lastEdited><Created>2022-01-04T12:33:02.2804917</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Marc</firstname><surname>Evans</surname><order>1</order></author><author><firstname>Angharad R.</firstname><surname>Morgan</surname><order>2</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>3</order></author><author><firstname>Sarah</firstname><surname>Davies</surname><order>4</order></author><author><firstname>Debbie</firstname><surname>Hicks</surname><order>5</order></author><author><firstname>Pam</firstname><surname>Brown</surname><order>6</order></author><author><firstname>Zaheer</firstname><surname>Yousef</surname><order>7</order></author><author><firstname>Umesh</firstname><surname>Dashora</surname><order>8</order></author><author><firstname>Adie</firstname><surname>Viljoen</surname><order>9</order></author><author><firstname>Hannah</firstname><surname>Beba</surname><order>10</order></author><author><firstname>W. David</firstname><surname>Strain</surname><order>11</order></author></authors><documents><document><filename>59059__22587__ccf99b33d44941c2b4435a5df6f19e0b.pdf</filename><originalFilename>59059.pdf</originalFilename><uploaded>2022-03-14T13:15:10.5293816</uploaded><type>Output</type><contentLength>782136</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9;The Author(s) 2022. This article is licensed under a Creative Commons Attribution NonCommercial 4.0 International License</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2022-03-14T13:17:06.2808758 v2 59059 2022-01-04 Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2022-01-04 BMS While glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, are among the most effective drugs for treating people with type 2 diabetes (T2D), they are clinically under-utilised. Until recently, the only route for semaglutide administration was via subcutaneous injection. However, an oral formulation of semaglutide was recently licensed, with the potential to address therapy inertia and increase patient adherence to treatment, which is essential in controlling blood glucose and reducing complications. The availability of oral semaglutide provides a new option for both clinicians and patients who are reluctant to use an injectable agent. This has been of particular importance in addressing the challenge of virtual diabetes care during the COVID-19 pandemic, circumventing the logistical problems that are often associated with subcutaneous medication administration. However, there remains limited awareness of the clinical and economic value of oral semaglutide in routine clinical practice. In this article, we present our consensus opinion on the role of oral semaglutide in routine clinical practice and discuss its value in reducing the burden of delivering diabetes care in the post-COVID-19 pandemic period of chronic disease management. Journal Article Diabetes Therapy 13 2 225 240 Springer Science and Business Media LLC 1869-6953 1869-6961 Glucagon-like peptide-1 receptor agonists; Oral semaglutide; Type 2 diabetes 1 2 2022 2022-02-01 10.1007/s13300-021-01201-z COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University 2022-03-14T13:17:06.2808758 2022-01-04T12:33:02.2804917 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Marc Evans 1 Angharad R. Morgan 2 Steve Bain 0000-0001-8519-4964 3 Sarah Davies 4 Debbie Hicks 5 Pam Brown 6 Zaheer Yousef 7 Umesh Dashora 8 Adie Viljoen 9 Hannah Beba 10 W. David Strain 11 59059__22587__ccf99b33d44941c2b4435a5df6f19e0b.pdf 59059.pdf 2022-03-14T13:15:10.5293816 Output 782136 application/pdf Version of Record true ©The Author(s) 2022. This article is licensed under a Creative Commons Attribution NonCommercial 4.0 International License true eng http://creativecommons.org/licenses/by-nc/4.0/
title Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice
spellingShingle Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice
Steve Bain
title_short Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice
title_full Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice
title_fullStr Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice
title_full_unstemmed Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice
title_sort Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
author Steve Bain
author2 Marc Evans
Angharad R. Morgan
Steve Bain
Sarah Davies
Debbie Hicks
Pam Brown
Zaheer Yousef
Umesh Dashora
Adie Viljoen
Hannah Beba
W. David Strain
format Journal article
container_title Diabetes Therapy
container_volume 13
container_issue 2
container_start_page 225
publishDate 2022
institution Swansea University
issn 1869-6953
1869-6961
doi_str_mv 10.1007/s13300-021-01201-z
publisher Springer Science and Business Media LLC
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description While glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, are among the most effective drugs for treating people with type 2 diabetes (T2D), they are clinically under-utilised. Until recently, the only route for semaglutide administration was via subcutaneous injection. However, an oral formulation of semaglutide was recently licensed, with the potential to address therapy inertia and increase patient adherence to treatment, which is essential in controlling blood glucose and reducing complications. The availability of oral semaglutide provides a new option for both clinicians and patients who are reluctant to use an injectable agent. This has been of particular importance in addressing the challenge of virtual diabetes care during the COVID-19 pandemic, circumventing the logistical problems that are often associated with subcutaneous medication administration. However, there remains limited awareness of the clinical and economic value of oral semaglutide in routine clinical practice. In this article, we present our consensus opinion on the role of oral semaglutide in routine clinical practice and discuss its value in reducing the burden of delivering diabetes care in the post-COVID-19 pandemic period of chronic disease management.
published_date 2022-02-01T04:16:04Z
_version_ 1763754077849649152
score 11.012947

Similar Items